Open access · OA
via Europe PMC
Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives.
Biomolecules · 2026
Deregulated nutrient-sensing
Altered intercellular communication
Cell culture / in vitro
Human
Review
Abstract
Renal fibrosis represents the final common pathway of chronic kidney disease (CKD) progression and remains a major therapeutic challenge. Fibroblast growth factor receptor 3 (FGFR3) has emerged as a context-dependent component of fibroblast growth factor (FGF) signaling, but its renal role remains incompletely defined because direct receptor-specific evidence is scarce. This review integrates kidney-specific FGFR3 studies with endocrine FGF23-Klotho biology and broader FGF/FGFR networks using an explicit evidence hierarchy. Current direct renal evidence is limited to two 2025 experimental studies: an FGF18-associated FGFR3-AMPK-NOX4 program that attenuated folic acid-induced fibrosis, and a single toxicant model reporting an FGF9-FGFR3-PI3K/Akt program associated with fibroblast proliferation. The latter requires independent replication before generalization beyond toxicant nephropathy. By contrast, physiological renal FGF23 signaling is best established through FGFR1c-α-Klotho, whereas the strongest evidence for Klotho-independent pathological FGF23 signaling involves FGFR4 in cardiovascular tissues; direct evidence that FGF23 promotes renal fibrosis specifically through FGFR3 is lacking. Accordingly, FGFR3 should be viewed as an emerging, ligand- and compartment-dependent signaling component rather than a validated CKD therapeutic target. Future priorities include human kidney spatial and phosphoproteomic profiling, cell-specific FGFR3 perturbation, longitudinal FGF23/Klotho biomarker studies, and mechanism-based evaluation of FGFR-directed strategies with integrated renal and mineral-metabolism endpoints.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/biom16101431
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Y, F., H, W., L, W., & H., W. (2026). Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives. <em>Biomolecules</em>. https://doi.org/10.3390/biom16101431
Vancouver
Y F, H W, L W, H. W. Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives. Biomolecules. 2026. doi:10.3390/biom16101431.
BibTeX
@article{fu2026Emergi,
title = {Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives.},
author = {Fu Y and Wang H and Wang L and Wang H.},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16101431},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2026
Open access · CC-BY
Klotho and FGF23: endocrine regulation of kidney disease outcomes
Biomolecules 2026
Open access · OA
Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives
Hypertension 2021
Citation only
Role of Klotho in the Development of Essential Hypertension
Kidney International Supplements 2014
Open access · OA
Fibrosis and renal aging
Pharmaceutics 2021
Open access · CC-BY
Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease
Cells 2026
Open access · OA